2nd World Congress on Interventional Therapies for Type 2 Diabetes

<strong>2nd</strong> <strong>World</strong> <strong>Congress</strong> on 

Interventional Therapies for Type 2 Diabetes 

March 28-30, 2011 

Hilton New York • New York, NY • USA 

<strong>Congress</strong> Director 

Francesco Rubino, MD 

<strong>Congress</strong> Program 

www.wcidt.org 

Hosted By

Welcome to the <strong>2nd</strong> <strong>World</strong> <strong>Congress</strong> on 

Interventional therapies for Type 2 diabetes 

Dear Colleagues and Friends, 

Several gastrointestinal (GI) operations originally designed to treat morbid obesity also 

cause dramatic improvement or even remission of type 2 diabetes. The mechanisms 

by which surgery controls hyperglycemia remain elusive. Increasing evidence suggests 

that weight-independent mechanisms may play a role in the surgical control of diabetes. 

This knowledge challenges current paradigms of disease pathogenesis and points to the 

gastrointestinal tract as a potential target for the development of less invasive interventional 

therapies and novel pharmaceuticals. 

Previously, the Diabetes Surgery Summit (Rome 2007) and the 1st <strong>World</strong> <strong>Congress</strong> on 

Interventional Therapies for Type 2 Diabetes (New York 2008), have raised attention about 

the role of gastrointestinal surgery for the treatment of diabetes: opportunities and 

limitations of this emerging field are now the matter of a growing debate. 

The debate continues with the <strong>2nd</strong> <strong>World</strong> <strong>Congress</strong> on Interventional Therapies for Type 2 

Diabetes. A multidisciplinary group of clinicians, scientists and policy makers will address 

barriers that still prevent access to surgical treatment of diabetes in eligible patients and 

develop an agenda of research priorities to improve patients selection and elucidate 

mechanisms of diabetes control. 

A stellar Faculty of leading international scientists will also discuss how the lessons learned 

from study of gastrointestinal interventions may improve understanding of diabetes and 

provide a lead for future treatments of curative intent. 

On behalf of the organizing committee and myself, I welcome you to this exciting, 

multidisciplinary event. 


<strong>Congress</strong> Director 

1



EDUCATIONAL PARTNER 

American Diabetes Association 

ENDORSING SOCIETIES 

The <strong>2nd</strong> <strong>World</strong> <strong>Congress</strong> on Interventional Therapies for Type 2 Diabetes is endorsed by the following organizations. 

 

100 SW 75th Street Suite 201 

Gainesville, FL 32607 

American Association of 

Clinical Endocrinologists 

American Association of 

Endocrine Surgeons 

American Gastroenterological 

Association 

American Society for Metabolic 

and Bariatric Surgery 

Asociacion 

De Cirugia Bariatrica 

Y Metabolica De 

Guatemala 

Asia Pacific, Metabolic & 

Bariatric Surgery Society 

Asociation Latinoamericana 

De Circurjanos Endoscpistas 

Association for the 

Study of Obesity 

Belgian Endocrine Society 

Canadian Diabetes 

Association 

Diabetes UK 

Emirates Obesity 

Surgery 

Interest Group 

European Association 

for Gastroenterology 

and Endoscopy 

European Association for 

the Study of Diabetes 

IFSO Sweden 

Indian Association of Gastrointestinal 

Endo-Surgeons 

International Atherosclerosis 

Society 

Endocrine Society 

European Association for 

Endoscopic Surgery 

International Federation for the Surgery 

of Obesity and Metabolic Disorders 

2 

<strong>2nd</strong> <strong>World</strong> <strong>Congress</strong> on Interventional Therapies for Type 2 Diabetes • March 28-30, 2011 • New York, NY, USA • www.wcidt.org



Italian Society of 

Endocrinology 

Japan Society for the Study 

of Obesity 

National Obesity Forum 

The New York 

Academy of Sciencs 

Obesity & Metabolic Surgery 

Society of India 

The Obesity Society 

Obesity Surgery Society of 

Australia & New Zealand 

The Philippine Society for 

Metabolic and Bariatric Surgery 

Qatar Diabetes 

Association – Qatar Foundation 

Research Society 

for the Study of 

Diabetes in India 

Sociedad Argentina 

de Diabetes 

Sociedade Brasileira de Cirurgia 

Bariatrica e Metabolica 

Sociedade Brasileira 

de Diabetes (SBD) 

Sociedade Brasileira de 

Endocronologia e Metabologia 

Sociedad de Cirujanos 

de Chile 

Sociedad Espanola 

de Diabetes 

Società 

Italiana 

di Diabetologia 

Società Italiana dell'Obesità 

Società Italiana di Chirurgia dell’Obesità 

e delle malattie metaboliche 

Società Italiana per la 

Prevezione Cardiovascolare 

Society for 

Endocrinology 

Society of American Gastrointestinal 

and Endoscopic Surgeons 

The Society for Surgery 

of the Alimentary Tract 

Swiss Society for the Study of Morbid 

Obesity and Metabolic Disorders 

This program is supported in name only by the American Heart Association’s Councils on Basic Cardiovascular Sciences, 

Clinical Cardiology, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, Kidney in CV Disease, 

and High Blood Pressure Research. http://www.heart.org/HEARTORG/ 

<strong>2nd</strong> <strong>World</strong> <strong>Congress</strong> on Interventional Therapies for Type 2 Diabetes • March 28-30, 2011 • New York, NY, USA • www.wcidt.org 

3

<strong>2nd</strong> <strong>World</strong> <strong>Congress</strong> on Interventional Therapies for Type 2 Diabetes 

The International Diabetes Federation (IDF) 

Position Statement on 

Interventional Treatments of Type 2 Diabetes 

During the <strong>World</strong> <strong>Congress</strong>, the IDF will officially announce its Position Statement on 

Metabolic/Bariatric Surgery and GI Interventions for the Treatment of Diabetes 

Monday, March 28, 2011 

11:10 am - 12:30 pm • Grand Ballroom, Hilton New York 

The IDF consensus developing meeting was held at the IDF head office in Brussels, Belgium (5-6 December, 2010). 

This meeting was convened by: 

Professor George Alberti 

Imperial College, London and Newcastle University, UK 

Professor John B. Dixon 

Baker IDI Heart & Diabetes Institute, Melbourne, Australia 

Professor Paul Zimmet 

Baker IDI Heart & Diabetes Institute, Melbourne, Australia 

Professor Francesco Rubino 

Weill Cornell Medical College, New York, NY, USA 

Professor Stephanie Amiel 

King's College London, UK 

Professor Louise A. Baur 

University of Sydney, Australia 

Professor Nam H. Cho 

Ajou University School of Medicine, Korea 

Dr. Bruno Geloneze 

University of Campinas (UNICAMP), Brazil 

Professor Jan Willem Greve 

Atrium Medical Center, Netherlands 

Professor Linong Ji 

Peking University People's Hospital, China 

Dr. Muffazal Lakdawala 

Saifee Hospital, India 

Professor Wei-Jei Lee 

Ming-Sheng General Hospital, National Taiwan 

University, Taiwan 

Other attendees at the meeting were: 

Professor Pierre Lefebvre 

IDF and University of Liege, Belgium 

Dr. Carel Le Roux 

Imperial College London, UK 

Professor Jean-Claude Mbanya 

International Diabetes Federation, Cameroon 

Professor Gertrude Mingrone 

Catholic University of Rome, Italy 

Professor Philip R. Schauer 

Cleveland Clinic Lerner College of Medicine, USA 

Professor Luc Van Gaal 

Antwerp University Hospital, Belgium 

Dr. David Whiting 

International Diabetes Federation, Belgium 

Professor Bruce M. Wolfe 

Oregon Health and Science University (OHSU), USA 

All panel members made a substantial contribution to the meeting and subsequent formulation of the position statement. 

The consensus meeting was supported with an unrestricted educational grant by: 

Allergan Inc, Irvine, CA, USA 

Ethicon, Ethicon Endo-Surgery, Inc, Cincinnati, Ohio, USA 

MetaCure Inc, Mount Laurel, NJ, USA 

These companies played no role in the discussion or preparation of the IDF position statement. 

4 




Contents 

Welcome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 

Endorsing Societies . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2-3 

International Diabetes Federation Statement. . . . . . . . . . . . . . . 

General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . 

4 

6-7 

<strong>Congress</strong> Advisory Committee . . . . . . . . . . . . . . . . . . . . . . . 9 

<strong>Congress</strong> Program Committee . . . . . . . . . . . . . . . . . . . . . 11-13 

Distinguished Faculty . . . . . . . . . . . . . . . . . . . . . . . . . . 14-21 

Guest Experts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 

Program-At-A-Glance . . . . . . . . . . . . . . . . . . . . . . . . . 23-24 

PROGRAM 

Monday, March 28. . . . . . . . . . . . . . . . . . . . . . . . . . 

Tuesday, March 29. . . . . . . . . . . . . . . . . . . . . . . . . . 

26-27 

28-32 

Breakout Sessions/Workshops . . . . . . . . . . . . . . . . . . . 30-32 

Wednesday, March 30. . . . . . . . . . . . . . . . . . . . . . . . 33-34 

Faculty Index. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 

Exhibitor Directory . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37-38 

Exhibit Floor Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 

Poster Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 

Diabetes: A Global Epidemic . . . . . . . . . . . . . . . . . . . . . . . 41 

Gastrointestinal Procedures . . . . . . . . . . . . . . . . . . . . . . 43-47 

Disclosures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48-49 

<strong>Congress</strong> Sponsors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50


GENERAL INFORMATION 

The <strong>World</strong> <strong>Congress</strong> will take place March 28-30, 2011 

at the Hilton New York, 1335 Avenue of the Americas, New York, NY 10013 

Telephone: (+1) 212-586-7000 • Guest Fax: (+1) 212-315-1374 

EDUCATIONAL DISCLAIMER 

The primary purpose of this congress is education. Information 

presented, as well as publications, technologies, and/or services 

discussed, are intended to inform you about the knowledge, 

techniques, and experiences of the faculty who are willing to 

share such information with colleagues. A diversity of 

professional opinions exists on the topics of the <strong>Congress</strong>, and 

the views of the conference’s faculty are solely for educational 

purposes. Faculty’s views neither represent those of the <strong>2nd</strong> 

<strong>World</strong> <strong>Congress</strong> on Interventional Therapies for Type 2 Diabetes 

nor constitute endorsement by the endorsing societies listed in 

this syllabus. The <strong>Congress</strong> declaims any and all liability or 

damages to any individual attending this conference and for 

all claims, which may result from the use of information, 

publications, technologies, products and/or services of the 

meeting. Faculty disclosure statements have been provided 

by speakers and are included at the end of this syllabus. 

ACCREDITATION 

Due to the structure and multidisciplinary nature of the <strong>Congress</strong>, 

continuing medical education and nursing credits are not 

available through the <strong>Congress</strong> this year. 

GUIDE TO MEETING ROOMS 

Second Floor 

• Promenade - <strong>World</strong> <strong>Congress</strong> Registration 

• Clinton Suite - Press Office 

• Gibson Suite - Speaker Ready Room 

• Rhinelander Gallery - Exhibits, Poster Sessions, 

Continental Breakfasts and Lunches 

• Sutton Center - Breakout Sessions 

• Sutton North/Beekman - Breakout Sessions 

• Sutton South/Regent - Breakout Sessions 

Third Floor 

• Grand Ballroom - Opening Ceremony, Plenary Sessions 

• Trianon Ballroom - Welcome Reception 

All meeting room floors being used for the <strong>World</strong> <strong>Congress</strong> 

are accessible by elevators. Escalators also provide access 

between First, Second, and Third Floors. 

SPEAKER READY ROOM 

All <strong>Congress</strong> speakers are required to check in at the Speaker 

Ready Room no later than two hours in advance of your 

presentation. The Speaker Ready Room is located in the 

Gibson Suite on the hotel’s second floor. 

Speaker Ready Room Hours: 

Sunday, March 27, 2011 2:00 pm - 6:00 pm 

Monday, March 28, 2011 7:00 am - 6:00 pm 

Tuesday, March 29, 2011 6:30 am - 6:00 pm 

Wednesday, March 30, 2011 7:00 am - 12:00 pm 

REGISTRATION 

Registration Hours: 

Sunday, March 27, 2011 


Tuesday, March 29, 2011 

Wednesday, March 30, 2011 

10:30 am - 7:00 pm 

7:00 am - 9:00 pm 

6:30 am - 7:00 pm 

7:00 am - 2:00 pm 

Only registered participants may attend the Scientific Sessions 

and the Social Events offered by the <strong>World</strong> <strong>Congress</strong>. 

All registered participants are entitled to: 

• Attend all Scientific Sessions 

• Attend the Exhibits, and the Poster Sessions 

• Receive Final Program and Abstracts 

• Breakfast and Coffee Breaks March 28-30 and Boxed 

Lunches on March 28-29 

BADGES 

The official badge must be worn for admission to all activities of 

the <strong>Congress</strong>. 

PRESS 

Working press from print and electronic media may receive 

complimentary registration on submission of a copy of press 

credentials and a completed registration form. A Press Office 

will be available in the Clinton Suite on the <strong>2nd</strong> floor. 

Press Office Hours: 


Tuesday, March 29, 2011 

Wednesday, March 30, 2011 

7:00 am - 6:00 pm 

7:00 am - 6:00 pm 

7:00 am - 12:00 pm 

6 


SCIENTIFIC EXHIBITS 

Scientific Exhibits and Posters will be located inside the 

Rhinelander Gallery on the hotel’s second floor. Exhibit and 

poster hours are: 

Monday, March 28 

7:00 am - 6:45 pm 

(Poster Session from 5:45 – 6:45 pm) 

Tuesday, March 29 

6:30 am – 3:00 pm 

LANGUAGE 

The official language of the <strong>Congress</strong> is English. No simultaneous 

translation is provided. 

WIFI HOTSPOT 

A wifi hotspot is offered to participants to remotely access 

Internet. The wifi hotspot is located inside the Rhinelander 

Ballroom. Funding for the <strong>2nd</strong> <strong>World</strong> <strong>Congress</strong> wifi hotspot is 

graciously provided by Allergan. 

MEALS & COFFEE BREAKS 

Continental breakfast and box lunch will be available inside the 

Rhinelander Gallery on Monday and Tuesday. Coffee breaks, as 

well as Wednesday’s continental breakfast, will be located in 

the Grand Ballroom Foyer. 

WELCOME RECEPTION 

Please join us for this unique opportunity to network with faculty, 

guest experts and colleagues. Areas of conversation will be 

nestled among tastes and flavors reminiscent of New York 

Neighborhoods. Relax and enjoy the music of the best cover 

band in New York City ~ Café Wha ~ with your colleagues 

and friends to your favorite funk, classic rock, rhythm and and 

meringue dance music. 

Trianon Ballroom, Hilton New York 


8:00 pm - 10:00 pm 

Tickets to the Welcome Reception are available for purchase at 

the Registration Desk until 12:00 pm on Monday, March 28. A 

ticket and official <strong>Congress</strong> badge are required for admittance. 

CERTIFICATE OF ATTENDANCE 

A Certificate of Attendance is available upon request, from the 

Registration Desk at the end of the <strong>Congress</strong>. The request form 

may be found in your registration bag. 

BUSINESS CENTER 

A fully staffed Business Center is located on the <strong>2nd</strong> floor of 

the New York Hilton, adjacent to Guest Elevators (next to the 

Madison Suite). Services include computer stations, Fax 

Services, Copy Machine, and Package Delivery. 

Business Center Hours: 

Monday - Friday 

Saturday & Sunday 

7:00 am - 7:00 pm 

9:00 am - 5:00 pm 

The Business Center may also be accessed 24 hours a day 

using your New York Hilton guest room key. The Business 

Center can be contacted though a house phone at Ext. 5212 

or by calling (+1) 212-399-1977. 

LOST & FOUND 

Please return all lost or found items to the Registration Desk. 

All items left at the <strong>World</strong> <strong>Congress</strong> Lost and Found will be 

turned over to New York Hilton upon conclusion of the event. 

IN CASE OF EMERGENCY 

In the event of any emergency situation, dial extension 5747 or 

66 from any house phone or your hotel room. New York Hilton 

has security personnel trained in first aid and CPR and a direct 

link to NYC emergency services such as ambulance and 

paramedics to render aid quickly. 

SMOKING 

The New York Hilton sleeping rooms, public and meeting space 

is 100% smoke-free. There is a “Smoking Oasis” out front of 

the Hotel on the main ramp. 

PERSONAL INSURANCE COVERAGE 

Registration for the <strong>World</strong> <strong>Congress</strong> implies that the participant 

agrees that neither the Organizing Committee (consisting of the 

Advisory and Program Committees), the Weill Cornell Medical 

College, the NewYork-Presbyterian Hospital nor the Giovanni 

Lorenzini Medical Foundation assume any liability or responsibility 

whatsoever. <strong>Congress</strong> delegates are requested to make their 

own arrangements for medical, travel, and personal insurance. 

CELLULAR PHONES, BEEPERS & ELECTRONIC DEVICES 

In consideration of fellow participants, it is requested that all cell 

phones, beepers, pagers, and other electronic devices be 

turned off or set to the silent/vibrate mode during all Scientific 

Sessions to avoid disruption. 

AMERICANS WITH DISABILITIES STATEMENT 

The <strong>World</strong> <strong>Congress</strong> wishes to take those steps to ensure that 

no individual with a disability is excluded, denied services, 

segregated, or otherwise related to differently because of the 

absence of auxiliary aids and services identified in the Americans 

with Disabilities Act. If any such services are necessary in order 

to participate in the <strong>Congress</strong>, please communicate your needs 

in advance. 

The <strong>Congress</strong> can assist with special needs (e.g. physical, 

dietary). For assistance, please stop by the Registration Desk. 

PROGRAM CHANGES AND MESSAGE BOARD 

A Program Change and Message Board is located in the 

Registration Area on the <strong>2nd</strong> Floor Promenade, where any last 

minute changes to the Program will be posted. 

CANCELLATION OF THE CONGRESS 

In the unlikely event that the <strong>2nd</strong> <strong>World</strong> <strong>Congress</strong> on 

Interventional Therapies for Type 2 Diabetes is abbreviated or 

cancelled for any reason whatsoever, the Weill Cornell Medical 

College, the NewYork-Presbyterian Hospital and the Giovanni 

Lorenzini Medical Foundation and Fondazione Giovanni 

Lorenzini reserve the right, in their sole discretion, to unilaterally 

terminate the <strong>Congress</strong>. In such case, the registrant and/or any 

funding/supporting organization hereby agrees to waive any 

claim against the Weill Cornell Medical College, the NewYork- 

Presbyterian Hospital and the Giovanni Lorenzini Medical 

Foundation and Fondazione Giovanni Lorenzini, for damages or 

compensation including but not limited to, fees for registration, 

housing, airfare, and incidental charges. 

<strong>2nd</strong> <strong>World</strong> <strong>Congress</strong> on Interventional Therapies for Type 2 Diabetes • March 28-30, 2011 • New York, NY, USA • www.wcidt.org 7

TAB 

Committees & Faculty

BLANK 

Back of Tab Page


<strong>Congress</strong> Advisory Committee 

CONGRESS DIRECTOR 


Chief, GI Metabolic Surgery 

Director, Diabetes Surgery Center 

Weill Cornell Medical College 

NewYork-Presbyterian Hospital 

New York, NY USA 

M. Sue Kirkman, MD 

Senior Vice President, Medical Affairs 

and Community Information 


Alexandria, VA USA 

Linda Cann, MSEd 

Managing Director, Professional Education, 

Conventions and International Affairs 



Ricardo V. Cohen, MD 

Co-Director 

The Center for the Surgical Treatment of 

Morbid Obesity & Metabolic Disorder 

Alemão Oswaldo Cruz Hospital 

São Paulo, Brazil 

Harold E. Lebovitz, MD 

Professor, Medicine 

SUNY Health Science Center at Brooklyn 

Brooklyn, NY USA 

Fabrizio Michelassi, MD 

Lewis Atterbury Stinson Professor and 

Chairman 

Department of Surgery 


Surgeon-in-Chief 

NewYork-Presbyterian Hospital/Weill 

Cornell Medical Center 


David E. Cummings, MD 


Metabolism, Endocrinology & Nutrition 

Deputy Director, Diabetes Endocrinology 

Research Center 

University of Washington School of Medicine 

Seattle, WA USA 

Alfons Pomp, MD, FRCSC, FACS 

Leon C. Hirsch Professor of Surgery 

Chief, Section Laparoscopic & Bariatric 

Surgery 



Antonio M. Gotto, Jr., MD, DPhil 

The Stephen and Suzanne Weiss Dean 


Provost, Medical Affairs 



Philip Schauer, MD 

Professor, Surgery 

Lerner College of Medicine 

Director, Advanced Laparoscopic & 

Bariatric Surgery 

Cleveland Clinic 

Cleveland, OH USA 

Lee M. Kaplan, MD, PhD 


Harvard Medical School 

Director, MGH Weight Center 

Massachusetts General Hospital 

Boston, MA USA 

Paul Zimmet, MD, PhD 

Director Emeritus 

Director International Research 

Baker IDI Heart and Diabetes Institute 

Melbourne, Australia 



Program Committee 

CONGRESS DIRECTOR 







CLINICAL TRACK 

CHAIR 





CO-CHAIR 

Phillip Schauer, MD 







RESEARCH TRACK 

CHAIR 








CO-CHAIR 

Lee Kaplan, MD, PhD 






POLICY TRACK 

CHAIR 






CO-CHAIR 

David R. Flum, MD, MPH 


Associate Chair, Research 

University of Washington 



11



Domenico Accili, MD 


Director, Diabetes and Endocrinology 


Columbia University 


Allison B. Goldfine, MD 

Associate Professor, Medicine 


Section Head, Clinical Research 

Joslin Diabetes Center 


Louis J. Aronne, MD, FACP 

Clinical Professor, Medicine 

Director, Comprehensive Weight Control 

Program 









Co-Director 


Morbid Obesity & Metabolic Disorder 



Samuel Klein, MD 

William H. Danforth Professor of Medicine 

and Nutritional Science 

Washington University School of Medicine 

St. Louis, MO USA 

John B. Dixon, MBBS, PhD, 

FRACGP, FRCPEdin 

NHMRC Senior Research Fellow, Vascular 

and Hypertension-Obesity Research 



Rudolph L. Leibel, MD 

Christopher J. Murphy Memorial Professor 

of Diabetes Research 

Co-Director, Naomi Berrie Diabetes 

Center; 

Head, Division of Molecular Genetics 

Columbia University Medical Center 


Robin S. Goland, MD 

Professor of Clinical Medicine and 

Pediatrics 

Columbia University College of 

Physicians & Surgeons 


Carel W. Le Roux, MB, ChB 

Reader, Investigative Science 

Department of Medicine 

Imperial College 

London, UK 

12 




Timothy E. McGraw, PhD 

Professor, Biochemistry 



Jesse Roth, MD, FACP 


Albert Einstein College of Medicine 

Investigator, 

Feinstein Institute for Medical Research 

Manhasset, NY USA 

Jeffrey I. Mechanick, MD 


Endocrinology, Diabetes and Bone Disease 

Director, Metabolic Support 

Mount Sinai School of Medicine 


Bruce Wolfe, MD 


Oregon Health & Science University 

Portland, OR USA 


13


Distinguished Faculty 

Domenico Accili, MD 


Director, Diabetes & Endocrinology 




Louis J. Aronne, MD, FACP 


Director, Comprehensive Weight Control 

Program 



Ted D. Adams, PhD, MPH 

Program Director, 

Cardiovascular Genetics, 

University of Utah and Health Fitness 

Institute 

LDS Hospital, Intermountain Healthcare 

Salt Lake City, UT USA 

Nicola Basso, MD, FACS 


Paride Stefanini Department of Surgery 

Sapienza University of Rome 

Azienda Policlinico Umberto I 

Rome, Italy 

Sir K. George Alberti, MA, DPhil, 

BM BCh 

Senior Research Investigator, Medicine 



Richard N. Bergman, PhD 

Keck Professor of Medicine 

Chair, Department of Physiology and 

Biophysics 

Keck School of Medicine 

University of Southern California 

Los Angeles, CA USA 

Stephanie A. Amiel, MD 

RD Lawrence Professor, Diabetic Medicine 

King’s College 


Zachary T. Bloomgarden, MD 

Clinical Professor, Medicine, 

Endocrinology, Diabetes, & Bone Disease 



Caroline M. Apovian, MD 


Boston University School of Medicine 

Director, Nutrition and Weight 

Management 

Boston Medical Center 


Stacy A. Brethauer, MD 

Associate Staff Surgeon 

Laparoscopic & Bariatric Surgery 



14 




Michael S. Brown, MD 

W.A. (Monty) Moncrief Distinguished Chair, 

Cholesterol & Arteriosclerosis Research 

Regental Professor, Molecular Genetics 

The University of Texas Southwestern 

Medical Center 

Dallas, TX USA 

1985 Nobel Laureate for Medicine or 

Physiology 

Tamara Darsow, PhD 

Vice President Research Programs 



Henry Buchwald, MD, PhD 

Professor, Surgery and Biomedical 

Engineering 

University of Minnesota 

Minneapolis, MN USA 

Professor the Lord Ara Darzi of 

Denham, PC KBE HonFREng 

FmedSci 


Imperial College London 


Pradeep Chowbey, MD, FACS 

Chair, Minimal Access Surgery 

Joint Managing Director, Max Institute 

of Minimal Access, Metabolic & Bariatric 

Surgery 

New Delhi, India 

Aureo Ludovico De Paula, MD 

Director, Surgery 

Specialty Hospital 

Goias, Brazil 


Co-Director 


Morbid Obesity and Metabolic Disorder 



Ralph DeFronzo, MD 


Chief, Diabetes Division 

University of Texas Health Science 

Center 

San Antonio, TX USA 








Stefano Del Prato, MD 

Professor, Endocrinology and 

Metabolism 

Chief, Section of Diabetes 

University of Pisa 

Cisanello Hospital 

Pisa, Italy 




John B. Dixon, MBBS, PhD, 

FRACGP, FRCPEdin 

NHMRC Senior Research Fellow, 

Vascular and Hypertension-Obesity 

Research 



Michel Gagner, MD 

Clinical Professor, Surgery 

Clinique Michel Gagner MD, Inc. 

Montreal, QC Canada 

Robert H. Eckel, MD 


Professor, Physiology and Biophysics 

University of Colorado - Anshutz 

Medical Campus 

Aurora, CO USA 

Manoel Galvao Neto, MD 

Surgeon & Gastroenterologist 

Scientific Coordinator 

Gastro Obeso Center 


Ele Ferrannini, MD 

Professor, Internal Medicine 

University of Pisa 

Pisa, Italy 

Allison B. Goldfine, MD 



Section Head, Clinical Research 

Joslin Diabetes Center 


David R. Flum, MD, MPH 


Associate Chair, Research 



Joseph L. Goldstein, MD 

Julie and Louis A. Beecherl Distinguished 

Chair in Biomedical Science 

Regental Professor, Molecular Genetics 

The University of Texas Southwestern 

Medical Center 

Dallas, TX USA 

1985 Nobel Laureate for Medicine or 

Physiology 

John Funder, MD, PhD, FRACP, 

FRCP 


Prince Henry's Institute 

Clayton, Australia 

Antonio M. Gotto, Jr. , MD, DPhil 

The Stephen and Suzanne Weiss Dean 


Provost, Medical Affairs 



16 




Jan Willem M. Greve, MD, PhD 


Chair, Department of Surgery 

Atrium Medical Center Parkstad 

Heerleen, Limburg The Netherlands 

Shashank R. Joshi, MBBS, MD, 

DM 

Professor, Consultant 

Grant Medical College and Sir JJ Group 

of Hospitals 

Mumbai, India 

Peter Hill, MD, PhD 

Corporate Medical Director 

Medical Administration Department 

Hamad Medical Corporation 

Doha, Qatar 

Steven H. Kahn, MB, ChB 


VA Puget Sound Health Care System 



Bjorn Hofmann, MSc, PhD 

Professor, Medical Ethics 

Institute for Health and Society 

University of Oslo 

Oslo, Norway 

Lee Kaplan, MD, PhD 






Jens Juul Holst, MD 

Professor, Medical Physiology 

Institute of Biomedical Sciences 

Copenhagen, Denmark 

Catherine Keating, MPH 

Senior Research Fellow 

Deakin Health Economics, Faculty of 

Health 

Deakin University 


Linong Ji, MD 

Co-Director, Peking University Diabetes 

Center 

Director, Department Of Endocrinology 

And Metabolism, Peking University 

People’s Hospital 

President, Chinese Diabetes Society 

Vice President, 

Chinese Endocrinologist Association 

Beijing, China 









Samuel Klein, MD 

William H. Danforth Professor of 

Medicine and Nutritional Science 

Washington University School of 

Medicine 

St Louis, MO USA 

Carel W. Le Roux, MD, PhD 

Reader, Investigative Science 

Department of Medicine 



Judith Korner, MD, PhD 


Director, Weight Control Center 







Blandine B. Laferrere, MD 


Columbia University College of Physicians 

and Surgeons 


Frank Lefevre, MD 


Senior Scientist, BCBSA Technology 

Evaluation Center 

Northwestern Feinberg School of 

Medicine 

Chicago, IL USA 

Muffazal Abdulkader Lakdawala, MD 

Chief, Minimal Access & Bariatric Surgery 

Department 

Centre for Obesity and Diabetes Support 

Saifee Hospital 

Mumbai, India 

Rudolph L. Leibel, MD 

Christopher J. Murphy Memorial Professor 

of Diabetes Research 

Co-Director, Naomi Berrie Diabetes Center 

Head, Division of Molecular Genetics 



David Lautz, MD 

Director of Bariatric Surgery 

Harvard Medical School, Brigham and 

Women's Hospital 


Ruth E. Ley, PhD 

Assistant Professor, Microbiology 

Cornell University 

Ithaca, NY USA 

18 




Rui Li, PhD 

Health Economist 

Centers for Disease Control and 

Prevention 

Atlanta, GA USA 

Xavier Pi-Sunyer, MD 

Chief of Endocrinology and 

Professor of Medicine 

St. Luke’s Roosevelt Hospital 



Timothy E. McGraw, PhD 

Professor, Biochemistry 



Alfons Pomp, MD, FRCSC, 

FACS 

Leon C. Hirsch Professor of Surgery 

Chief, Section Laparoscopic & 




Jeffrey I. Mechanick, MD 

Clinical Professor, Medicine, 

Endocrinology, Diabetes and Bone 

Disease 

Director, Metabolic Support 



Walter J. Pories, MD, FACS 

Professor, Surgery, Biochemistry 

and Exercise and Sports Science 

East Carolina University 

Greenville, NC USA 

Geltrude Mingrone, MD, PhD 

Professor, Internal Medicine, 

Endocrinology 

Catholic University of the Sacred Heart 

Rome, Italy 

Jesse Roth, MD, FACP 


Albert Einstein College of Medicine 

Investigator, Feinstein Institute for 

Medical Research 

Manhasset, NY USA 

John J. Moore, DO, FAAFP 

Patient Management Medical Director 

for the Northeast Region 

AETNA 

Blue Bell, PA USA 








19



Mohammed Fathy Saoud, PhD 

President 

Qatar Foundation 

Doha, Qatar 

Lars V. Sjöström, MD, PhD 

Professor Emeritus, SOS Secretariate 

Internal Medicine 

Sahlgrenska University Hospital 

Göteborg, Sweden 

Phillip Schauer, MD 







Myrlene Staten, MD 

Senior Advisor, Diabetes Translational 

Research 

NIDDK, National Institutes of Health 

Bethesda, MD USA 

Gary Schwartz, PhD 

Professor of Medicine & Neuroscience 

Albert Einstein College of Medicine of 

Yeshiva University 

Bronx, NY USA 

Harvey J. Sugerman, MD 

Emeritus Professor, Surgery 

Editor-in-Chief, Surgery for Obesity and 

Related Diseases 

Virginia Commonwealth University 

Richmond, VA USA 

Randy J. Seeley, PhD 

Director, Cincinnati Diabetes Obesity Center 

University of Cincinnati 

Donald C. Harrison Endowed Professor 

in Medicine 

Metabolic Diseases Institute 

Cincinnati, OH USA 

Sean D. Sullivan, PhD 

Professor, Health Sciences and 

Department of Pharmacy 

Associate Dean for Research 

University of Washington School 

of Pharmacy 


Gerald I. Shulman, MD, PhD 

Investigator, Howard Hughes Medical Institute 

Professor, Physiological Chemistry, 

Medicine (Endocrinology) and Cellular & 

Molecular Physiology 

Associate Director, Diabetes-Endocrinology 


Associate Director, Medical Scientist Training 

Program 

Yale University School of Medicine 

New Haven, CT USA 

Tess Van Der Merwe, MBChB, PhD 

Director 

Centres of Excellence for Metabolic 

Medicine and Surgery 

Gauteng, South Africa 

20 




Bruce Wolfe, MD, FACS 


Oregon Health & Science University 

Portland, OR USA 






Carol H. Wysham, MD 

Clinical Associate Professor, Medicine 

University of Washington School of 

Medicine 

Section Head, Rockwood Center for 

Diabetes & Endocrinology 

Rockwood Clinic 

Spokane, WA USA 

Mahmoud Ali Zirie, MD 


Head, Endocrinology Diabetes Division 


Doha, Qatar 

James Young, MD 


Executive Dean 


Institute Chair 

Endocrinology & Metabolism Institute 





Guest Experts 

In addition to contributing to the scholarship of the audience, the presence of Guest Experts is meant to facilitate a lively 

discussion and debate throughout the course of the <strong>World</strong> <strong>Congress</strong>. Guest Experts will also steer group discussion during 

breakout sessions on Tuesday, March 29th. We would like to thank the following individuals for providing a unique 

perspective to the emerging field of interventional diabetology: 

Vince Aguirre, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . USA 

Luiz Vicente Berti, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . Brazil 

Morris J. Birnbaum, MD, PhD . . . . . . . . . . . . . . . . . . . . . . . USA 

Robin Blackstone, MD, FACS . . . . . . . . . . . . . . . . . . . . . . . USA 

Camilo Boza, MD, FACS . . . . . . . . . . . . . . . . . . . . . . . . . . Chile 

David J. Brillon, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . USA 

Marco Castagneto, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . Italy 

Lee-Ming Chuang, MD, PhD . . . . . . . . . . . . . . . . . . . . . . . Taiwan 

Gregory F. Dakin, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . USA 

Alex Escalona, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Chile 

Mathias A. Fobi, MD, FACS, FASMBS, FICS, FACN . . . . . . . USA 

Paolo Gentileschi, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Italy 

Giovanni Ghirlanda, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . Italy 

Ramen Goel, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . India 

Neil E. Hutcher, MD, FACS . . . . . . . . . . . . . . . . . . . . . . . . . USA 

William B. Inabnet, III, MD, FACS . . . . . . . . . . . . . . . . . . . . . USA 

Kazunori Kasama, MD, FACS . . . . . . . . . . . . . . . . . . . . . . Japan 

Subhash Kini, MD, FRCS, FACS . . . . . . . . . . . . . . . . . . . . . USA 

John G. Kral, MD, PhD, FACS . . . . . . . . . . . . . . . . . . . . . . . USA 

Wei-Jei Lee, MD, PhD . . . . . . . . . . . . . . . . . . . . . . . . . . . Taiwan 

Bassem M. Masri, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . USA 

Francois Pattou, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . France 

Antonio E. Pontiroli, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . Italy 

Almino Ramos, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Brazil 

Mitch Roslin, MD, FACS . . . . . . . . . . . . . . . . . . . . . . . . . . . USA 

Naina Sinha, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . USA 

April D. Strader, PhD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . USA 

Richard Stubbs, MD, FRCS, FRACS . . . . . . . . . . . . New Zealand 

Michel Suter, MD . . . . . . . . . . . . . . . . . . . . . . . . . . . Switzerland 

Julio Teixeira, MD, FACS . . . . . . . . . . . . . . . . . . . . . . . . . . . USA 

Antonio José Torres, MD, PhD . . . . . . . . . . . . . . . . . . . . . . Spain 

Jonathan A. Waitman, MD . . . . . . . . . . . . . . . . . . . . . . . . . USA 

22 


TAB 

Scientific Program

BLANK 

Back of Tabe Page


Program At-A-Glance 

MONDAY, MARCH 28, 2011 

7:00 am - 8:00 am Continental Breakfast (Rhinelander Gallery) 

7:00 am - 9:00 pm 

7:00 am - 6:45 pm 

8:00 am - 8:20 am 

8:20 am - 8:35 am 

Registration Open (<strong>2nd</strong> Floor Promenade) 

Exhibits and Posters (Rhinelander Gallery) 

Opening Ceremony (Grand Ballroom) 

Introduction of the <strong>World</strong> <strong>Congress</strong>: Scope and Methods 

F. Rubino (New York, NY USA) 

CLINICAL TRACK SESSION I 

8:35 am - 10:50 am 

(Grand Ballroom) 

Clinical Outcomes of Conventional and Surgical Treatments for T2DM 

10:50 am - 11:10 am Refreshment Break (Grand Ballroom Foyer) 

POLICY TRACK SESSION I (Grand Ballroom) 

11:10 am - 12:30 pm The International Diabetes Federation (IDF) Position Statement on Interventional 

Treatments of Type 2 Diabetes 

12:30 pm - 1:30 pm 

Lunch 

(Rhinelander Gallery) 

CLINICAL TRACK SESSION II (Grand Ballroom) 

1:30 pm - 3:00 pm CV Risk Reduction and Survival in Patients with Diabetes: Medical versus Surgical Therapy 

3:00 pm - 3:20 pm 

Refreshment Break (Grand Ballroom Foyer) 

CLINICAL TRACK SESSION III (Grand Ballroom) 

3:20 pm - 5:45 pm Diabetes Surgery: Indications, Choice of Procedure & Peri-Operative Management 

5:45 pm - 6:45 pm 

8:00 pm - 11:00 pm 

Poster Session (Rhinelander Gallery) 

Welcome Reception (Trianon Ballroom) 

TUESDAY, MARCH 29, 2011 

6:30 am - 7:30 am 

Continental Breakfast (Rhinelander Gallery) 

6:30 am - 7:00 pm 

6:30 am - 3:00 pm 


Exhibits and Posters (Rhinelander Gallery) 

RESEARCH TRACK SESSION I (Grand Ballroom) 

7:30 am - 9:40 am Mechanisms of Action of Surgery 

RESEARCH TRACK SESSION II (Grand Ballroom) 

9:40 am - 11:10 am Novel Experimental Approaches for Diabetes/Obesity 

11:10 am - 11:30 am 




TUESDAY, MARCH 29, 2011 (cont’d) 

RESEARCH TRACK SESSION III (Grand Ballroom) 

11:30 am - 1:00 pm Defining Priorities for Clinical Research in Metabolic/Diabetes Surgery 

1:00 pm - 2:00 pm 

Lunch 

(Rhinelander Gallery) 

POLICY TRACK SESSION II (Grand Ballroom) 

2:00 pm - 3:00 pm Global Burden of Diabetes and Resource Availability for Interventional Approaches 

POLICY TRACK SESSION III (Grand Ballroom) 

3:00 pm - 4:30 pm Cost Effectiveness of Diabetes Surgery: Implications for Public and Private Health 

Insurance 

4:30 pm - 4:50 pm 


BREAKOUT SESSIONS AND WORKSHOPS (Sutton Complex Rooms) 

4:50 pm - 6:50 pm Breakout Sessions 

Clinical (Sutton North/Beekman) 

Research (Sutton Center) 

Policy (Sutton South/Regent) 

WEDNESDAY, MARCH 30, 2011 

7:00 am - 2:00 pm 

7:00 am - 8:00 am 


Continental Breakfast (Grand Ballroom Lobby) 

KEYNOTE LECTURE 


8:00 am - 9:00 am 

Surviving Starvation: Essential Role of the Ghrelin-Growth Hormone Axis 

M.S. Brown (Dallas, TX USA) 

J.L. Goldstein (Dallas, TX USA) 

RESEARCH TRACK SESSION IV (Grand Ballroom) 

9:00 am - 10:40 am The Role of the Gut in the Physiology and Pathophysiology of Obesity and Diabetes 

10:40 am - 11:00 am 

PANEL DISCUSSION 

11:00 am - 12:00 pm 



The GI tract: Could it be the missing link between obesity and diabetes 

EXECUTIVE SUMMARIES/TAKE HOME MESSAGE (Grand Ballroom) 

12:00 pm - 1:15 pm Presentation of Executive Summaries and Conclusions 

1:20 pm 

<strong>World</strong> <strong>Congress</strong> Adjourns 

24 



Scientific Program 

MONDAY, MARCH 28, 2011 

7:00 am - 8:00 am 

CONTINENTAL BREAKFAST (Rhinelander Gallery) 

8:00 am - 8:20 am 

Grand Ballroom 

8:20 am - 8:35 am 

Grand Ballroom 

Opening Ceremony 

Introduction of the <strong>World</strong> <strong>Congress</strong>: Scope and Methods 


CLINICAL TRACK SESSION I 8:35 am - 10:50 am Grand Ballroom 

Clinical Outcomes of Conventional and Surgical Treatments for T2DM 

Chairs: W. Pories (Greenville, NC USA) • H.E. Lebovitz (Brooklyn, NY USA) 

8:35 am - 8:55 am 

8:55 am - 9:15 am 

9:15 am - 9:30 am 

9:30 am - 9:45 am 

9:45 am - 10:00 am 

10:00 am - 10:50 am 

10:50 am - 11:10 am 

Glycemic and metabolic control with current pharmacologic treatments 

S. Del Prato (Pisa, Italy) 

Glycemic and metabolic outcomes with bariatric/metabolic surgery: overview 

P. Schauer (Cleveland, OH USA) 

Long-term prevention and remission of diabetes after bariatric surgery in the SOS study 

L. Sjöström (Göteborg, Sweden) 

Safety profiles of pharmaceutical approaches 

H.E. Lebovitz (Brooklyn, NY USA) 

Safety profiles of surgical approaches: short and long term 

B.M. Wolfe (Portland, OR USA) 

Panel Discussion 

Panelists: S.A. Amiel (London, UK), Z.T. Bloomgarden (New York, NY USA), J. Dixon (Melbourne, 

Australia), A. Pomp (New York, NY USA), H. Buchwald (Minneapolis, MN USA), A.B. Goldfine (Boston, MA 

USA), K.G. Alberti (London, UK), J.I. Mechanick (New York, NY USA), X. Pi-Sunyer (New York, NY USA) 

COFFEE BREAK (Grand Ballroom Foyer) 

POLICY TRACK SESSION I 11:10 am - 12:30 pm Grand Ballroom 

The International Diabetes Federation (IDF) Position Statement on Interventional Treatments of Type 2 

Diabetes 

Chairs: J. Dixon (Melbourne, Australia) • K.G. Alberti (London, UK) 

11:10 am - 11:20 am 

11:20 am - 11:40 am 

11:40 am - 12.30 pm 

Existing guidelines for surgical treatment of obesity and diabetes (NIH, DSS, ADA) 

L.M. Kaplan (Boston, MA USA) 

The IDF position statement on interventional therapies for type 2 diabetes 

P. Zimmet (Melbourne, Australia) 


Panelists: C. Wysham (ADA) (Seattle, WA USA), J.I. Mechanick (AACE) (New York, NY USA), S.A. Amiel 

(Diabetes UK) (London, UK), X. Pi-Sunyer (NHLBI) (New York, NY USA), A.M. Gotto (New York, NY USA), 

F. Rubino (New York, NY USA), R.H. Eckel (Aurora, CO USA) 

12:30 pm - 1:30 pm 

LUNCH BREAK (Rhinelander Gallery) 

26 




CLINICAL TRACK SESSION II 1:30 pm - 3:00 pm Grand Ballroom 

CV Risk Reduction and Survival in Patients with Diabetes: Medical versus Surgical Therapy 

Chairs: A.M. Gotto (New York, NY USA) • K.G. Alberti (London, UK) 

1:30 pm - 1:50 pm 

1:50 pm - 2:05 pm 

2:05 pm - 2:15 pm 

2:15 pm - 3:00 pm 

3:00 pm - 3:20 pm 

CV risk, CVD and diabetes-related mortality: impact of pharmacologic approaches 

R.H. Eckel (Aurora, CO USA) 

Long-term (20 years) impact of bariatric surgery on CV risk and CVD: an update from the 

SOS study 

L. Sjöström (Göteborg, Sweden) 

The impact of bariatric/metabolic surgery on CV risk and long-term survival 

T.D. Adams (Salt Lake City, UT USA) 


Panelists: R. DeFronzo (San Antonio, TX USA), E. Ferrannini (Pisa, Italy), S.R. Joshi (Mumbai, India), S.E. 

Kahn (Seattle, WA USA), J. Young (Cleveland, OH USA), H.J. Sugerman (Richmond, VA USA), W. Pories 

(Greenville, NC USA) 


CLINICAL TRACK SESSION III 3:20 pm - 5:45 pm Grand Ballroom 

Diabetes Surgery: Indications, Choice of Procedure & Peri-Operative Management 

Chairs: L. Aronne (New York, NY USA) • J. Young (Cleveland, OH USA) 

3:20 pm - 3:35 pm 

3:35 pm - 3:50 pm 

3:50 pm - 4:05 pm 

4:05 pm - 4:40 pm 

4:40 pm - 4:55 pm 

4:55 pm - 5:15 pm 

5:15 pm - 5:45 pm 

Predicting factors of diabetes control/reasonable criteria for surgical indication 

J. Korner (New York, NY USA) 

Preoperative management of diabetic patients 

C.M. Apovian (Boston, MA USA) 

Which surgical procedure is best Summary of available evidence from comparative 

clinical studies in high and low BMI patients 

H.J. Sugerman (Richmond, VA USA) 


Panelists: H.E. Lebovitz (Brooklyn, NY USA), S.R. Joshi (Mumbai, India), J.I. Mechanick (New York, NY 

USA), J. Dixon (Melbourne, Australia), M. Gagner (Montreal, QC, Canada), R.V. Cohen (São Paulo, Brazil) 

Postoperative management of obese and diabetic patients; the role of 

integrated/multimodality therapies 

L. Aronne (New York, NY USA) 

A rational and physiologic approach to the management of diabetes after surgery 

R. DeFronzo (San Antonio, TX USA) 


Panelists: C. Wysham (Seattle, WA USA), S.E. Kahn (Seattle, WA USA), R.N. Bergman (Los Angeles, CA 

USA), L. Ji (Beijing, China), S. Del Prato (Pisa, Italy) 

5:45 pm - 6:45 pm 

8:00 pm 

POSTER SESSION (Rhinelander Gallery) 

WELCOME RECEPTION (Trianon Ballroom) 




TUESDAY, MARCH 29, 2011 

6:30 am - 7:30 am 

CONTINENTAL BREAKFAST (Rhinelander Gallery) 

RESEARCH TRACK SESSION I 7:30 am - 9:40 am Grand Ballroom 

Mechanisms of Action of Surgery 

Chairs: L.M. Kaplan (Boston, MA USA) • S.E. Kahn (Seattle, WA USA) 

7:30 am - 7:45 am 

7:45 am - 8:00 am 

8:00 am - 8:15 am 

8:15 am - 8:30 am 

8:30 am - 9:00 am 

8:30 am - 8:45 am 

8:45 am - 9:00 am 

9:00 am - 9:40 am 

Mechanisms of Weight Loss: beyond restriction and malabsorption 

R.J. Seeley (Cincinnati, OH USA) 

Effect of GI surgery on insulin secretion/sensitivity 

S. Klein (St. Louis, MO USA) 

Effects of GI surgery on food choices and energy expenditure 

C.W. Le Roux (London, UK) 

Effects of GI surgery on glucose homeostasis 

J.J. Holst (Copenhagen, Denmark) 

Debate: Diabetes control by GI surgery is explained by weight-independent mechanisms 

Yes: D.E. Cummings (Seattle, WA USA) 

No: E. Ferrannini (Pisa, Italy) 

Panel Discussion: Weight independent mechanisms of diabetes control: weighing the 

evidence 

Panelists: J. Korner (New York, NY USA), G. Mingrone (Rome, Italy), R.N. Bergman (Los Angeles, CA USA), 

R. DeFronzo (San Antonio, TX USA), B.B. Laferrere (New York, NY USA), G.J. Schwartz (New York, NY USA) 

RESEARCH TRACK SESSION II 9:40 am - 11:10 am Grand Ballroom 

Novel Experimental Approaches for Diabetes/Obesity 

Chairs: H. Buchwald (Minneapolis, MN USA) • S. Klein (St. Louis, MO USA) 

9:40 am - 9:55 am 

9:55 am - 10:10 am 

10:10 am - 10:25 am 

10:25 am - 10:40 am 

10:40 am - 11:10 am 

Novel GI surgical procedures (DJB and Ileal Interposition: alone and with associated sleeve 

gastrectomy) 

R.V. Cohen (São Paulo, Brazil) 

Endoluminal procedures for obesity/diabetes 

S.A. Brethauer (Cleveland, OH USA) 

Endoluminal devices for obesity/diabetes 

L.M. Kaplan (Boston, MA USA) 

Pacing/GI electric stimulation for diabetes 



Panelists: J.W.M. Greve (Heerleen, Netherlands), M. Galvao Neto (São Paulo, Brazil), A. De Paula (Goiania, 

Brazil), W. Pories (Greenville, NC USA), J. Funder (Clayton, Australia), S.R. Joshi (Mumbai, India) 

11:10 am - 11:30 am 

COFFEE BREAK (Grand Ballroom Lobby) 

28 




RESEARCH TRACK SESSION III 11:30 am - 1:00 pm Grand Ballroom 

Defining Priorities for Clinical Research in Metabolic/Diabetes Surgery 

Chairs: A.B. Goldfine (Boston, MA USA) • J. Roth (Manhasset, NY USA) 

11:30 am - 11:45 am 

11:45 am - 12:00 pm 

12:00 pm - 12:15 pm 

12:15 pm - 1:00 pm 

1:00 pm - 2:00 pm 

Clinical trials in diabetes surgery: overview of ongoing trials; challenges for study design, 

practical issues in surgical trials 

A.B. Goldfine (Boston, MA USA) 

Clinical trials in diabetes surgery: ethical aspects 

B.M. Hofmann (Oslo, Norway) 

Advantages and disadvantages of each design, multisite vs consortium model for large 

clinical trials 


Panel Discussion: Priorities for clinical research in diabetes surgery; costs/funding, ethical 

aspects 

Panelists: P. Schauer (Cleveland, OH USA), R. DeFronzo (San Antonio, TX USA), J. Korner (New York, 

NY USA), D. Lautz (Boston, MA USA), M. Staten (Bethesda, MD USA), F. Saoud (Doha, Qatar), T. Darsow 

(Alexandria, VA USA) 

LUNCH BREAK (Rhinelander Gallery) 

POLICY TRACK SESSION II 2:00 pm - 3:00 pm Grand Ballroom 

Global Burden of Diabetes and Resource Availability for Interventional Approaches 

Chairs: P. Zimmet (Melbourne, Australia) • P. Chowbey (New Delhi, India) 

2:00 pm - 2:15 pm 

2:15 pm - 2:30 pm 

2:30 pm - 3:00 pm 

The global epidemiology of diabetes 


The global costs of diabetes 

R. Li (Atlanta, GA USA) 

Panel Discussion: Specific regional challenges for diabetes prevention and treatment 

Panelists: L. Ji (Beijing, China), J. Funder (Clayton, Australia), T. Van Der Merwe (Pretoria, South Africa), 

A. Darzi (London, UK), M. Ali Zirie (Doha, Qatar), R. Li (Atlanta, GA USA) 

POLICY TRACK SESSION III 3:00 pm - 4:30 pm Grand Ballroom 

Cost Effectiveness of Diabetes Surgery: Implications for Public and Private Health Insurance 

Chairs: A. Darzi (London, UK) • D. Flum (Seattle, WA USA) 

3:00 pm - 3:15 pm 

3:15 pm - 3:30 pm 

3:30 pm - 3:45 pm 

3:45 pm - 4:30 pm 

Review of what we know about cost-effectiveness of bariatric surgery with special regard 

to patients with diabetes 

C. Keating (Burwood, Australia) 

How governments consider evidence on cost-effectiveness 

S.D. Sullivan (Seattle, WA USA) 

How payers consider the evidence of cost and effectiveness 

F. Lefevre (Chicago, IL USA) 

Panel Discussion: Simply cost-effective Reconciling cost-evaluations related to diabetes 

interventions 

Panelists: R. Li (Atlanta, GA USA), C. Keating (Burwood, Australia), S.D. Sullivan (Seattle, WA USA), 

F. Lefevre (Chicago, IL USA), J.J. Moore (Blue Bell, PA USA) 

4:30 pm - 4:50 pm COFFEE BREAK (Grand Ballroom Foyer) 


29



TUESDAY, MARCH 29, 2011 (continued) 

BREAKOUT SESSIONS AND WORKSHOPS 

4:50 pm - 6:50 pm 

Breakout Sessions for Interactive Discussion and Preparation of Executive Summary 

CLINICAL TRACK 4:50 pm - 6:50 pm Sutton North/Beekman 

Defining appropriate surgical candidates and good clinical practice for perioperative management and 

post-operative follow-up 

Chairs: H.E. Lebovitz (Brooklyn, NY USA) • P. Schauer (Cleveland, OH USA) 

4:50 pm - 5:25 pm 

4:50 pm - 4:55 pm 

4:55 pm - 5:10 pm 

5:10 pm - 5:25 pm 

Workshop A: Defining appropriate surgical candidates for diabetes surgery 

Who should be referred for surgical treatment of diabetes 


Expert Panel Comments 

W.J. Pories (Greenville, NC USA), L.J. Aronne (New York, NY USA), R. DeFronzo (San Antonio, TX USA), 

J. Young (Cleveland, OH USA) 

Q&A: Guest Experts and Audience 

Interactive Opinion Polls 

5:25 pm - 6:20 pm 

5:25 pm - 5:50 pm 

5:50 pm - 6:05 pm 

6:05 pm - 6:20 pm 

Workshop B: Defining ideal indications for each surgical procedure 

Which patients should undergo... 

Biliopancreatic Diversion/DS - A. Pomp (New York, NY USA) 

Sleeve Gastectomy - M. Gagner (Montreal, QC, Canada) 

Gastric Bypass - P. Schauer (Cleveland, OH USA) 

Gastric Banding - J.B. Dixon (Melbourne, Australia) 

Novel GI Procedures: To re-route or not to re-route the bowel - R.V. Cohen (São Paulo, Brazil) 


H. Buchwald (Minneapolis, MN USA), P. Chowbey (New Delhi, India), A.L. De Paula (Goiânia, Brazil), 

J.W.M. Greve (Heerleen, Netherlands) 



6:20 pm - 6:50 pm 

6:20 pm - 6:25 pm 

6:25 pm - 6:40 pm 

6:40 pm - 6:50 pm 

Workshop C: Defining and measuring success of surgical treatment of diabetes 

Definition of success and appropriate clinical measures to assess outcomes of surgical 

treatment 

J.I. Mechanick (New York, NY USA) 


H.J. Sugerman (Richmond, VA USA), J. Korner (New York, NY USA), R. DeFronzo (San Antonio, TX USA), 

S.R. Joshi (Mumbai, India) 



30 





4:50 pm - 6:50 pm 


RESEARCH TRACK 4:50 pm - 6:50 pm Sutton Center 

Defining priorities for clinical trials and investigations on mechanisms of action of surgery 

Chairs: L. Kaplan (Boston, MA USA) • D.E. Cummings (Seattle, WA USA) 

4:50 pm - 5:35 pm 

4:50 pm - 5:00 pm 

5:00 pm - 5:20 pm 

5:20 pm - 5:35 pm 

Workshop A: Defining mechanisms of action of surgery and their implications for future 

diabetes therapies and understanding of disease mechanisms 

Mechanisms of action of metabolic surgery: what is clear and what is not 

Lessons for future pharmacologic therapies 

Lessons about diabetes/obesity pathophysiology 

L. Kaplan (Boston, MA USA) 


G. Mingrone (Rome, Italy), G. Schwartz (Bronx, NY USA), B.B. Laferrere (New York, NY USA), 

R.N. Bergman (Los Angeles, CA USA) 



5:35 pm - 6:10 pm 

5:35 pm - 5:40 pm 

5:40 pm - 5:55 pm 

5:55 pm - 6:10 pm 

Workshop B: Defining appropriate methods of innovation in bariatric and metabolic 

surgery and novel interventional treatments for diabetes 

Defining proper clinical and pre-clinical assessment of new surgical procedures and devices 

C.W. Le Roux (London, UK) 


B.M. Hofmann (Oslo, Norway), M.Galvao Neto (São Paulo, Brazil), S. Klein (St. Louis, MO USA), S. Del Prato 

(Pisa, Italy) 



6:10 pm - 6:50 pm 

6:10 pm - 6:15 pm 

6:15 pm - 6:35 pm 

6:35 pm - 6:50 pm 

Workshop C: Defining priorities for clinical research 

Diabetes surgery: the most compelling clinical issues that require priority testing by 

randomized clinical trials 

D.E. Cummings (Seattle, WA USA) 


A.B. Goldfine (Boston, MA USA), M. Staten (Bethesda, MD USA), S.H. Kahn (Seattle, WA USA), 

X. Pi-Sunyer (New York, NY USA), D. Lautz (Boston, MA USA) 






TUESDAY, MARCH 29, 2011 (continued) 


4:50 pm - 6:50 pm 


POLICY TRACK 4:50 pm - 6:50 pm Sutton South/Regent 

Proposing practical solutions to improve access to surgery when indicated 

Chairs: P. Zimmet (Melbourne, Australia) • D. Flum (Seattle, WA USA) 

4:50 pm - 5:50 pm 

5:00 pm - 5:40 pm 

5:40 pm - 5:50 pm 

Workshop A: Creating a pathway to reconcile professional guidelines 


Panel Discussion/Round Table with official representatives of the following organizations: 

NHLBI Obesity Guidelines (X. Pi-Sunyer, New York, NY USA), ADA (M.S. Kirkman, Alexandria, VA USA), 

AACE (J.I. Mechanick, New York, NY USA), ASMBS (B. Wolfe, Portland, OR USA), TOS (C.M. Apovian, 

Boston, MA USA), SBCBM (R.V. Cohen, São Paulo, Brazil), SICOB (N. Basso, Rome, Italy), IFSO 

(M. Lakdawala, Mumbai, India) 


5:50 pm - 6:50 pm 

6:00 pm - 6:40 pm 

6:40 pm - 6:50 pm 

Workshop B: Payer perspectives: creating a pathway for policymakers and payers to 

reconcile approaches 

D. Flum (Seattle, WA USA) 

Panel Discussion/Round Table 

F. Lefevre (Chicago, IL USA), S.D. Sullivan (Seattle, WA USA), J. Funder (Clayton, Australia), L. Ji (Beijing, 

China), C. Keating (Buswood, Australia), T. Van Der Merwe (Pretoria, South Africa), P. Hill (Doha, Qatar), 

J.J. Moore (Blue Bell, PA USA) 


32 




WEDNESDAY, MARCH 30, 2011 

7:00 am - 8:00 am 

CONTINENTAL BREAKFAST (Grand Ballroom Foyer) 

KEYNOTE LECTURE 8:00 am - 9:00 am Grand Ballroom 

8:00 am - 9:00 am 

Surviving Starvation: Essential Role of the Ghrelin-Growth Hormone Axis 

M.S. Brown (Dallas, TX USA) 

J.L. Goldstein (Dallas, TX USA) 

The Nobel Prize in Physiology or Medicine 1985 was awarded jointly to Michael S. Brown and 

Joseph L. Goldstein “for their discoveries concerning the regulation of cholesterol metabolism”. 

RESEARCH TRACK SESSION IV 9:00 am - 10:40 am Grand Ballroom 

The role of the gut in the physiology and pathophysiology of obesity and diabetes 

Chairs: T.E. McGraw (New York, NY USA) • D. Accili (New York, NY USA) 

9:00 am - 9:20 am 

9:20 am - 9:40 am 

9:40 am - 10:00 am 

10:00 am - 10:20 am 

10:20 am - 10:40 am 

Conventional paradigm of the pathophysiology of obesity 

R.L. Leibel (New York, NY USA) 

Conventional paradigm of the pathophysiology of diabetes 

R.N. Bergman (Los Angeles, CA USA) 

The physiologic role of the gut in energy and glucose homeostasis 

J.J. Holst (Copenhagen, Denmark) 

The role of intestinal microbiota in insulin resistance, obesity/diabetes 

R.E. Ley (Ithaca, NY USA) 

Impaired GI physiology in individuals with diabetes/obesity 


10:40 am - 11:00 am 


PANEL DISCUSSION 11:00 am - 12:00 pm Grand Ballroom 

The GI tract: could it be the missing link between obesity and diabetes 

11:00 am - 11:05 am 

11:05 pm - 12:00 pm 

Introduction 



M.S. Brown (Dallas, TX USA), J.L. Goldstein (Dallas, TX USA), G. Shulman (New Haven, CT USA), 

S. Klein (St. Louis, MO USA), R. DeFronzo (San Antonio, TX USA), S.E. Kahn (Seattle, WA USA), 

J. Roth (Manhasset, NY USA), L.M. Kaplan (Boston, MA USA) 




WEDNESDAY, MARCH 30, 2011 (continued) 

EXECUTIVE SUMMARIES/TAKE HOME MESSAGE 12:00 pm - 1:15 pm Grand Ballroom 

Presentation of Executive Summaries and Conclusions 

Chairs: M. Sue Kirkman (Alexandria, VA USA) • W. Pories (Greenville, NC USA) 

12:00 pm - 12:12 pm 

12:12 pm - 12:24 pm 

12:24 pm - 12:36 pm 

12:36 pm - 12:48 pm 

12:48 pm - 1:00 pm 

1:00 pm - 1:15 pm 

1:15 pm - 1:20 pm 

Clinical Practice 


Priorities for Clinical Research 


Reconciling Guidelines 


Public Health Policies 

D. Flum (Seattle, WA USA) 

The evolving paradigm of diabetes pathogenesis 

J. Roth (Manhasset, NY USA) 

INTERACTIVE OPINION POLLS 

CLOSING REMARKS 

34 



A 

Accili, Domenico . . . . . . . . . . . . . . . . . . . . . . . . . . . 

Adams, Ted D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 

B 

Basso, Nicola . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32 

Bergman, Richard N. . . . . . . . . . . . . . . . . . . 27, 28, 31, 33 

Bloomgarden Zachary T. . . . . . . . . . . . . . . . . . . . . . . 26 

Brethauer, Stacy A. . . . . . . . . . . . . . . . . . . . . . . . . . 28 

Brown, Michael S. . . . . . . . . . . . . . . . . . . . . . . . . . . 33 

Buchwald, Henry . . . . . . . . . . . . . . . . . . . . . . 26, 28, 30 

C 

Chowbey, Pradeep . . . . . . . . . . . . . . . . . . . . . . . 29, 30 

Cohen, Ricardo V. . . . . . . . . . . . . . . . . . . . 27, 28, 30, 32 

Cummings, David E. . . . . . . . . . . . . . . . . . 28, 31, 33, 34 

D 

Darsow, Tamara . . . . . . . . . . . . . . . . . . . . . . . . . . . 

Darzi, Ara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 

E 

Eckel Robert H. . . . . . . . . . . . . . . . . . . . . . . . . . 

F 

Ferrannini, Ele . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 28 

Flum, David R. . . . . . . . . . . . . . . . . . . . . . . . 29, 32, 34 

Funder, John . . . . . . . . . . . . . . . . . . . . . . . . 28, 29, 32 

H 

Hill, Peter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32 

Hofmann, Bjørn M. . . . . . . . . . . . . . . . . . . . . . . . 29, 31 

Holst, Jens Juul . . . . . . . . . . . . . . . . . . . . . . . . . 28, 33 

K 

Kahn, Steven H. . . . . . . . . . . . . . . . . . . . . . 27, . 28, 31, 33 

Kaplan, Lee M. . . . . . . . . . . . . . . . . . . . . . 26, 28, 31, 33 

Keating, Catherine . . . . . . . . . . . . . . . . . . . . . . . . 29, 32 

Kirkman, M. Sue . . . . . . . . . . . . . . . . . . . . . . . . . 32, 34 

Klein Samuel . . . . . . . . . . . . . . . . . . . . . . . . . 28, 31, 33 

Korner, Judith . . . . . . . . . . . . . . . . . . . . . . 27, 28, 29, 30 

Faculty Index 

33 

27 

Alberti, K. George . . . . . . . . . . . . . . . . . . . . . . . . 26, 27 

Amiel, Stephanie A. . . . . . . . . . . . . . . . . . . . . . . . . . 26 

Apovian, Caroline M. . . . . . . . . . . . . . . . . . . . . . . 27, 32 

Aronne, Louis . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 30 

29 

29 

DeFronzo, Ralph . . . . . . . . . . . . . . . . . 27, 28, 29, 30, 33 

De Paula, Aureo . . . . . . . . . . . . . . . . . . . . . . . . . 28, 30 

Del Prato, Stefano . . . . . . . . . . . . . . . . . . . . . 26, 27, 31 

Dixon, John . . . . . . . . . . . . . . . . . . . . . . . . . 26, 27, 30 

26, 27 

G 

Gagner, Michel . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 30 

Galvao Neto, Manoel . . . . . . . . . . . . . . . . . . . . . . 28, 31 

Goldfine Allison B. . . . . . . . . . . . . . . . . . . . . . . 26, 29, 31 

Goldstein, Joseph L. . . . . . . . . . . . . . . . . . . . . . . . . . 33 

Gotto, Antonio M. . . . . . . . . . . . . . . . . . . . . . . . . 26, 27 

Greve, Jan Willem M. . . . . . . . . . . . . . . . . . . . . . . 28, 30 

J 

Ji, Linong . . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 29, 32 

Joshi, Shashank R. . . . . . . . . . . . . . . . . . . . . . 27, 28, 30 

L 

Laferrere, Blandine B. . . . . . . . . . . . . . . . . . . . . . 28, 31 

Lakdawala, M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32 

Lautz, David B. . . . . . . . . . . . . . . . . . . . . . . . . . 29, 31 

Lebovitz, Harold E. . . . . . . . . . . . . . . . 26, 27, 28, 30, 34 

Lefevre, Frank . . . . . . . . . . . . . . . . . . . . . . . . . . 29, 32 

Leibel, Rudolph L. . . . . . . . . . . . . . . . . . . . . . . . . . . 33 

LeRoux, Carel W. . . . . . . . . . . . . . . . . . . . . . . . . 

Ley Ruth, E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 

Li, Rui . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 

M 

McGraw, Timothy E. . . . . . . . . . . . . . . . . . . . . . . . . . 33 

Mechanick, Jeffrey I. . . . . . . . . . . . . . . . . . 26, 27, 30, 32 

Mingrone, Geltrude . . . . . . . . . . . . . . . . . . . . . . . 28, 31 

Moore, J.J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29, 32 

P 

Pi-Sunyer, Xavier . . . . . . . . . . . . . . . . . . . . . . 26, 31, 32 

Pomp, Alfons . . . . . . . . . . . . . . . . . . . . . . . . . . . 26, 30 

Pories, Walter J. . . . . . . . . . . . . . . . . . 26, 27, 28, 30, 34 

R 

Roth, Jesse . . . . . . . . . . . . . . . . . . . . . . . . . 29, 33, 34 

Rubino, Francesco . . . . . . . . . . . . . . . . . . . . . 26, 29, 33 

S 

Saoud, Moh'd. Fathy . . . . . . . . . . . . . . . . . . . . . . . . 29 

Schauer, Phillip . . . . . . . . . . . . . . . . . . . . . . . 26, 29, 30 

Schwartz, Gary J. . . . . . . . . . . . . . . . . . . . . . . . . 28, 31 

Seeley, Randy J. . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 

Shulman, Gerald . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 

Sjöström, Lars V. . . . . . . . . . . . . . . . . . . . . . . . . 26, 27 

Staten, Myrlene . . . . . . . . . . . . . . . . . . . . . . . . . 29, 31 

Sugerman, Harvery J. . . . . . . . . . . . . . . . . . . . . . 27, 30 

Sullivan, Sean D. . . . . . . . . . . . . . . . . . . . . . . . . 29, 32 

V 

Van Der Merwe, Tess . . . . . . . . . . . . . . . . . . . . . . 

W 

Wolfe, Bruce M. . . . . . . . . . . . . . . . . . . . . . . . . . 

Wysham, Carol H. . . . . . . . . . . . . . . . . . . . . . . . . 

Y 

Young, James . . . . . . . . . . . . . . . . . . . . . . . . . . 

28, 31 

33 

29 

29, 32 

26, 32 

26, 27 

27, 30 

Z 

Zimmet, Paul . . . . . . . . . . . . . . . . . . . . . . 26, 29, 32, 34 

Zirie, Mahmoud Ali . . . . . . . . . . . . . . . . . . . . . . . . . . 29 


35

Share the <strong>World</strong> <strong>Congress</strong> 

with your Staff and Colleagues! 

Pre-Purchase your <strong>Congress</strong> DVD today! 

The information presented at the <strong>2nd</strong> <strong>World</strong> <strong>Congress</strong> on 

Interventional Therapies for Type 2 Diabetes is an invaluable 

resource. The <strong>Congress</strong> DVD is the perfect way to share 

all the valuable information you’ve heard here with your 

colleagues and staff. 

The <strong>Congress</strong> DVD will include the full session 

recordings and slides from all presentations during 

the <strong>Congress</strong>, including the discussions in each 

of the three breakout tracks. 

Purchase the DVD at the <strong>Congress</strong> Registration Desk 

or after the <strong>Congress</strong> at www.wcidt.org 

Cost: $165 (plus shipping) 

DVD orders will be mailed in summer 2011.

TAB 

Scientific Exhibits

BLANK 

Back of Tab Page


EXHIBITOR DIRECTORY 

American Diabetes Foundation 

Booth 207 

Linda Cann 

+1.703.299.2068 

lcann@diabetes.org 

The American Diabetes Association is the leading non-profit 

organization focused on providing resources to health care 

professionals and people with diabetes to improve care and 

patient outcomes. The association has a worldwide professional 

membership of over 15,000 and over 425,000 lay members. 

Join the new grassroots movement to “Stop Diabetes.” 

Allergan 

Booth 104 

Pat Allen 

+1.714.246.4667 

allen_pat@allergan.com 

Allergan has joined the effort to fight the growing obesity 

epidemic with the LAP-BAND ® Adjustable Gastric Banding 

System, the first minimally invasive surgical approach approved 

in the United States by the FDA, to help patients achieve 

sustained weight loss, realize their goals for healthy living, and 

reduce obesity-related risks. 

Covidien 

Booth 100 

Gaurav Lamba 

+1.203.821.4770 

Gaurav.Lamba@covidien.com 

Gina Baldo 

+1.203.821.4770 

gina.baldo@covidien.com 

Covidien is a leading global healthcare products company that 

creates innovative medical solutions for better patient outcomes 

and delivers value through clinical leadership and excellence. 

Covidien manufactures a diverse range of industry-leading 

products in five segments including Surgical and Energy-based 

Devices. Please visit www.covidien.com to learn more. 

Ethicon Endo-Surgery 

Booth 102 

Annie Havens 

+1.513.337.8645 

ahavens@its.jnj.com 

Ethicon Endo-Surgery, a Johnson & Johnson company, 

develops and markets advanced medical devices for minimally 

invasive and open surgical procedures, focusing on procedureenabling 

devices for the interventional diagnosis and treatment 

of conditions in general and bariatric surgery, as well as 

gastrointestinal health, gynecology and surgical oncology. 

More information can be found at www.ethiconendo.com. 

GI Dynamics 

Booth 106 

Wade Fox 

+1.781.357.3306 

wfox@gidynamics.com 

GI Dynamics is focused on developing effective, non-surgical 

approaches for treating type 2 diabetes and obesity. The 

company's patented EndoBarrier technology has the potential 

to deliver medical innovations for people combating diabetes 

and weight problems or diabetes risk factors. Data from clinical 

trials demonstrate that the EndoBarrier may provide rapid 

improvement in glycemic control and significant weight loss by 

modifying metabolic pathways. 

Gore Medical Products 

Booth 202 

Pamela Hickey 

+1.410.506.8283 

phickey@wlgore.com 

Gore Medical Products Division has provided creative 

therapeutic solutions to complex medical problems for three 

decades. During that time, more than 35 million Innovative 

Gore Medical Devices have been implanted, saving and 

improving the quality of lives worldwide. The extensive Gore 

Medical family of products includes vascular grafts, endovascular 

and interventional devices, surgical materials for hernia repair, 

soft tissue reconstruction, staple line reinforcement, and sutures 

for use in vascular, cardiac and general surgery. 


Karl Storz Endoscopy-America Inc. 

Booth 204 

Julia Benoit 

+1.800.421.0837 

jbenoit@ksea.com 

KARL STORZ Endoscopy-America, a leader for 65 years in 

endoscopy technologies, has earned a reputation for more 

than its high-quality products. The company is also well 

regarded for its commitment to advancing medical technology 

and research programs. Among these is dedication to the 

research of Interventional Therapies for Type II Diabetes. 

Qatar Foundation and 


Booth 203 

Ramez Jaber 

+9.744.454.0855 

rjaber@qf.org.qa 

Qatar Foundation for Education, Science and Community 

Development (QF) is supporting Qatar on its journey from 

carbon economy to knowledge economy by unlocking human 

potential. This will not just benefit Qatar. It will benefit the world. 

QF is a private, non-profit organization founded in 1995 by His 

Highness Sheikh Hamad Bin Khalifa Al-Thani, Amir of Qatar. 

Its Chairperson and main driving force is Her Highness Sheikha 

Moza Bint Nasser. 

QF carries out its mission through three strategic pillars: 

education, science and research, and community development. 

QF’s education pillar brings world-class universities to Qatar to 

help create an education sector in which young people can 

develop the attitudes and skills required for a knowledge 

economy. Meanwhile, its science and research pillar builds 

Qatar's innovation and technology capacity by developing 

and commercializing solutions through key sciences. Finally, 

its community development pillar helps foster a progressive 

society while also enhancing cultural life, protecting Qatar’s 

heritage and addressing immediate social needs in the 

community. 

For a complete list of QF’s initiatives and projects, visit 

http://www.qf.org.qa 

Rhinelander Gallery - Exhibits and Posters 

WIFI 

HOTSPOT 

AREA 

206 204 202 

207 205 203 

106 104 102 

200 

201 

100 

ENTRANCE 

38 


TAB 

Posters

BLANK 

Back of Tab Page


Please refer to the Abstract Book for 

POSTER SESSIONS 

Rhinelander Gallery 

Poster Display and Viewing: 

Monday, March 28: 7:00 am - 6:45 pm 

Tuesday, March 29: 6:30 am - 3:00 pm 

Poster Sessions: 

One of the authors is required to attend his or her poster as follows. 

The formal poster session will be on Monday March 28 from 5:45 pm-6:45 pm. 

The Presenting Author is highlighted in bold 

Please refer to the Abstract Book for the complete listing of Poster Sessions and Abstracts 

An Author Index is included immediately following the Abstracts Listing. 

*Special Note: Posters marked with YIA are competing for the Young Investigator Award. 


39

40 <strong>2nd</strong> <strong>World</strong> <strong>Congress</strong> on Interventional Therapies for Type 2 Diabetes • March 28-30, 2011 • New York, NY, USA • www.wcidt.org

TAB 

Additional Resources

BLANK 

Back of Tab Page


Diabetes: A Global Epidemic 

■ 

■ 

■ 

■ 

■ 

■ 

■ 

■ 

■ 

Diabetes currently affects 285 million people worldwide 

and is expected to affect 438 million by 2030. 

In 2010, the five countries with the largest numbers of 

people with diabetes were India (50.8 million), China 

(43.2 million), the United States (26.8 million), Russia 

(9.6 million), and Brazil (7.6 million). 

In 2010, the five countries with the highest diabetes 

prevalence in the adult population were Nauru (30.9%), 

United Arab Emirates (18.7%), Saudi Arabia (16.8%), 

Mauritius (16.2%), and Bahrain (15.4%). 

By 2030, the largest increases in diabetes prevalence will 

take place in developing countries. 

Each year a further 7.7 million people develop diabetes. 

Each year 4 million deaths are attributable to diabetes. 

An even greater number die from cardiovascular disease 

made worse by diabetes-related lipid disorders and 

hypertension. 

Every 10 seconds a person dies from diabetes-related 

causes. 

Every 10 seconds two people develop diabetes. 

Diabetes is the fourth leading cause of global death by 

disease. 

■ 

■ 

■ 

■ 

■ 

■ 

■ 

Type 2 diabetes has become the most frequent 

condition in people with kidney failure in countries of the 

Western world. The reported incidence varies 

between 30% and 40% in countries such as Germany 

and the USA. 

10% to 20% of people with diabetes die of renal failure. 

It is estimated that more than 2.5 million people 

worldwide are affected by diabetic retinopathy. 

Diabetic retinopathy is the leading cause of vision 

loss in adults of working age (20 to 65 years) in 

industrialized countries. 

On average, people with type 2 diabetes will die 5-10 

years before people without diabetes, mostly due to 

cardiovascular disease. 

Cardiovascular disease is the major cause of death in 

diabetes, accounting for some 50% of all diabetes 

fatalities, and much disability. 

People with type 2 diabetes are over twice as likely to 

have a heart attack or stroke as people who do not have 

diabetes. Indeed, people with type 2 diabetes are as likely 

to suffer a heart attack as people without diabetes who 

have already had a heart attack. 

■ 

At least 50% of all people with diabetes are unaware of 

their condition. In some countries this figure may reach 

80%. 

■ 

■ 

At least 60% of new cases of type 2 diabetes is 

preventable by adopting a healthy diet and increasing 

physical activity. 

Diabetes is the largest cause of kidney failure in developed 

countries and is responsible for huge dialysis costs. 

Sources: 

Diabetes Atlas, fourth edition, 

International Diabetes Federation, 2009. 

Diabetes Fact Sheets: 

Time to Act, International Diabetes Federation, 2004. 

<strong>World</strong> Health Organisation Diabetes Unit - www.who.int/diabetes. 

Diabetes currently affects 285 million people worldwide, 

according to the International Diabetes Federation (IDF). 


Conventional Bariatric/Metabolic Procedures 

Roux-en-Y Gastric Bypass (RYGB) 

After its first report by Edward Mason in 1967, the 

technique of gastric bypass has undergone several 

modifications. The current technique involves the use of 

a surgical stapler to create a small and vertically oriented 

gastric pouch usually less than 30 cc in size. The upper 

pouch, which is completely divided from the gastric 

remnant is anastomosed to the jejunum (between 30 and 

75 cm from the ligament of Treitz). Bowel continuity is 

restored by an entero-entero anastomosis between the 

excluded biliary limb and the alimentary limb usually 

75-to 100 cm distal to the gastro-jejunostomy. After 

RYGB, ingested food bypasses approximately 95% of 

the stomach, the entire duodenum and a portion of the 

jejunum, but bile and nutrients mix in the distal jejunum 

and can be absorbed through the remaining portion of 

the small bowel (jejunum-ileum). 



Laparoscopic Adjustable Gastric Banding (LAGB) 

The LAGB is a restrictive procedure that involves encircling 

the upper part of the stomach with a band-like, saline-filled 

tube just distal to the gastroesophageal junction. The 

amount of restriction may be adjusted by injecting or 

withdrawing saline solution from the hollow core of the 

band through a subcutaneous port. 

Sleeve Gastrectomy (SG) 

Sleeve gastrectomy is a component of BPD-DS; an operation 

that can be performed in two stages (sleeve gastrectomy 

first, followed by the intestinal rearrangement months 

later) to reduce operative time and minimize surgical risk in 

super-obese patients (BMI>60). The dramatic weight loss 

consequent to the first stage of the BPD-DS has 

encouraged the use of SG as a stand-alone procedure. 

In addition to reducing the capacity of the stomach, SG 

eliminates the ghrelin-rich gastric fundus and can cause 

changes in intra-gastric pressure and gastric motility, all 

of which might play a role in the mechanism of action of 

the operation. Sleeve gastrectomy has been also shown to 

substantially improve diabetes in severely obese patients 

as well as in experimental rodent models of diabetes. The 

long-term (>5 years) clinical efficacy of the procedure is still 

under investigation. 

44 



Figure 1A 

Biliopancreatic Diversion (BPD) and BPD-DS 

The operation involves a gastric resection (usually leaving 

behind a 200-500 ml sized stomach) + a long intestinal 

bypass. The gastric resection can be horizontal as in the 

Scopinaro procedure (Fig 1A) or vertical - “sleeve 

gastrectomy” in its variant named “BPD-Duodenal 

Switch”- Fig 1B). The remnant stomach is anastomosed 

to the distal 250 cm of small intestine (called alimentary 

limb). The excluded small intestine (including the 

duodenum, the jejunum and part of the proximal ileum) 

carries the bile and pancreatic secretions (biliary limb) and 

is connected to the alimentary channel just 50-100 cm 

proximal to the ileocecal valve. The short segment of small 

bowel where bile and nutrients mix is called “common 

limb” and is the only site where fat and starches are 

absorbed, whereas the alimentary limb (usually 200-250 

cm in length) allows only partial absorption of nutrients. 

Figure 1B 


Investigational Gastrointestinal Procedures 

Figure 2A 

Duodenal-Jejunal Bypass (DJB) 

Originally described by Rubino as an experimental 

procedure to investigate mechanisms of action of gastric 

bypass surgery, the operation consists of a stomachpreserving 

bypass of a short segment of proximal small 

intestine, equivalent to the amount of intestine bypassed 

in a standard gastric bypass (RYGB). A variant of this 

procedure includes the association of proximal intestinal 

bypass with sleeve resection of the stomach (DJB-SG- 

Fig 2B) to reduce potential for marginal ulcerations and 

potentially increase clinical efficacy. These procedures 

have been used to treat diabetes in low BMI patients 

(R. Cohen and others). Long-term efficacy data are not 

yet available and these procedures should be considered 

investigational in humans. 

Figure 2B 

46 


Investigational Gastrointestinal Procedures 

Ileal Interposition (IT) 

The concept of ileal-interposition was first described by 

Koopmans and Sclafani in rodents experiments as a 

weight loss procedure. A small segment of ileum with its 

vascular and nervous supplies intact, is surgically interposed 

into the proximal small intestine, accelerating its exposure 

to ingested nutrients. IT can be performed alone or in 

association with sleeve gastrectomy and duodenal exclusion. 

The procedure requires a minimum of 3 anastomosis 

(vs the 2 of gastric bypass operations) and is technically 

complex, especially when associated with sleeve 

gastrectomy or duodenal exclusion. Early human studies 

suggest that these procedures can improve diabetes in 

non-obese subjects; however, long-term metabolic 

sequalae are unknown, and long-term safety is still to be 

evaluated. The procedure should be considered 

experimental in humans. 



Disclosures 

Faculty Disclosures 

Apovian, Caroline M. 

Consultant: Amylin, Orexigen, Allergan, Pfizer, Johnson & 

Johnson, Abott, Merck, GI Dynamics 

Grant/Research: Atkins Foundation, MetaProteomics, Amylin, 

Orexigen 

Aronne, Louis J. 

Contracted Research: Amylin Pharmaceuticals, Inc., 

F. Hoffmann-La Roche Ltd., Novo Nordisk, Orexigen 

Therapeutics, Inc. 

Consultant/Advisory Boards: Abbott Laboratories, Amylin 

Pharmaceuticals, Inc., GI Dynamics, Inc., Roche Laboratories, 

Inc., Johnson & Johnson, NeuroSearch, Inc., Novo Nordisk, 

Orexigen Therapeutics, Inc., VIVUS, Inc., GlaxoSmithKline 

Consumer Healthcare, LP 

Ownership Interest: Cardiometabolic Support Network, LLC 

Bergman, Richard N. 

Consultant: Tethys 

Grant/Research Support (Principal): Amylin 

Bloomgarden, Zachary T. 

Consultant: BMS/AZ, Merck, Novo Nordisk 

Speaker’s Bureau: Merck, Novo Nordisk, GlaxoSmithKlien, 

BMS BI 

Stock Shareholder (self managed): Bard, CVS, Roche, Novartis, 

St. Jude 

Brethauer, Stacy A. 

Consultant: Ethicon Endo 

Speaker’s Bureau: Ethicon Endo, Covidien 

Grant/Research Support (Principal): Bard/Davol, Ethicon Endo 

Buchwald, Henry 

Consultant: Ethicon Endo-Surgery, Fulfillium, Metacure 

Grant/Reserach Support (Principal): Meacure, Ethicon 

Endo-Surgery, WE Gore 

Stock Shareholder (self managed): Metacure 

Cummings, David E. 

Grant/Research (Principal): Johnson & Johnson, Ethicon 

Endosurgery 

Darsow, Tamara 

Stock Shareholder (self managed): Amylin 

Darzi, Ara 

Consultant: Covidien 

DeFronzo, Ralph 

Consultant: Takeda, Amylin, ISIS, Boehringer Ingelheim 

Speaker’s Bureau: Novo Nordisk 

Grant/Reserach Support (Principle): Takeda, Amylin 

Del Prato, Stefano 

Speaker’s Bureau: GlaxoSmithKline, Sanofi-Aventis 

Grant/Research Support (Principle): Merck & Co., Sanofi-Aventis, 

Novo Nordisk 

Advisory Panels: Novartis Pharmaceuticals, Merck & Co., 

Roche Pharmaceuticals, Roche Diagnostics Corporation, Pfizer 

Inc., Eli Lilly & Co., Amylin Pharmaceuticals, Inc., Mannkind 

Corporation; Boehringer Ingelheim, Bristol-Meyers Squibb, 

Novo Nordisk 

Dixon, John B. 

Consultant: Allergan Inc., Metagenics (Bariatric Advantage), 

Scientific Intake 

Speaker’s Bureau: Metagencis (Bariatirc Advantage), Eli Lilly, 

Nestle Australia, Optifast Medical Advisory Board 

Grant/Research (Principal): Allergan Inc., Nestle Australia, Optifast 

Medical Advisory Board, ResMed, Scientific Intake 

Course Director: Florida Hospital 

Course Co-Director: MISS 

Funder, John 

Consultant: Pfizer, Merck, CBio, Allergan, Novo NorDisk 

Gagner, Michel 

Speaker’s Bureau: Ethicon, Olympus, CineMed, Coviden 

Grant/Research Support (Principal): GORE 

Galvao Neto, Manoel 

Consultant: Ethicon Endo Surgery, GI Dynamics 

Greve, Jan Willem M. 

Consultant: GI Dynamics 

Grant/Research Support (Principal): GI Dynamics 

Kahn, Steven H. 

Consultant: Boenringer Ingelheim, Eli Lilly, GlaxoSmithKlien, 

Intarcia Therapeutics, Merck, Novo Nordisk 

Grant/Research: Daiichi Sankyo 

Kaplan, Lee 

Consultant: GI Dynamics 

Grant/Research (Principal): GI Dynamics 

Keating, Catherine 

Grant/Research Support (Principal): Allergan Health 

Klein, Samuel 

Consultant: Amylin, Dannon/Yakult, Ethicon Endosurgery, 

Merck, Orexigen, Takeda Pharmaceuticals, Vivus 

Pharmaceuticals 

Speaker’s Bureau: Merck 

Grant/Research Support (Principal): National Institute of Health 

(NIH), Barnes-Jewish Hospital Foundation, DSM Nutritional 

Products, Endo-Ethicon Surgery, Pfizer 

Stockholder: Aspirations Medical Technologies 

Endowments: Atkins Foundation Charitable Trust, Kilo 

Foundation 

Korner, Judith 

Grant/Research Support (Principal): Covidien 

Scientific Advisory Board: Nutrisystem 

Lautz, David 

Grant/Research (Principal): Covidien 

Lebovitz, Harold E. 

Consultant: Amylin Corporation, Astra-Zeneca, Biocon Pharma, 

Enzymotec, Glaxo Smith Kline (International), MetaCure, 

Sanofi-Aventis 

Speaker’s Bureau: Glaxo Smith Kline (International) 

Stockholder: Merck 

Advisory Board: Amylin Corporation, ATTCC, Biocon Pharma, 

Indigene, Intra Pharmaceuticals, Merck, MetaCure, Poxel Pharma 

48 



Disclosures 

Faculty Disclosures 

Pi-Sunyer, Xavier 

Consultant: Amylin, McNeil Nutritionals, Novo Nordiak, Vivus 

Inc., Weight Watchers, Orezigen 

Pories, Walter J. 

Consultant: Johnson & Johnson 

Grant/Research (Principal): Johnson & Johnson, GlaxoSmithKline 

Rubino, Francesco 

Consultant: NGM Biotech 

Grant/Research Support (Principal): Covidien, Roche 

Schauer, Phillip 

Consultant: Gore 

Grant/Research (Principal): Baxter, Covidien, Allergan 

Board of Directors: Remedy MD, Surgical Excellence LLC 

Scientific Advisory Board: Ethicon Endosurgery, Stryker 

Endoscopy, Bard-Davol, Barosense, Surgiquest, 

Cardinal/Snowden Pencer 

Seeley, Randy J. 

Consultant: Ethicon Endo 

Speaker’s Bureau: Novo Nordisk 

Grant/Research Support (Principal): Ethicon Endo, Novo 

Nordisk 

Sjöström, Lars V. 

Consultant: AZ, Johnson & Johnson, Several 

Grant/Research Support (Principle): Johnson & Johnson, 

Roche, Sanofi 

Wysham, Carol H. 

Consultant: Amylin Pharmaceuticals 

Speaker’s Bureau: Sanofi Aventis, Amylin Pharma 

Faculty With No Conflicts of Interest 

Accili, Domenico 

Adams, Ted D. 

Alberti, Sir K. George 

Amiel, Stephanie A. 

Basso, Nicola 

Brown, Michael S. 

Chowbey, Pradeep 

Cohen, Ricardo V. 

De Paula, Aureo Ludovico 

Eckel, Robert H. 

Ferrannini, Ele 

Flum, David R. 

Goldfine, Allison B. 

Goldstein, Joseph L. 

Gotto, Jr., Antonio M. 

Hill, Peter 

Hofmann, Bjorn 

Holst, Jens Juul Holst 

Ji, Linong 

Joshi, Shashank R. 

Kirkman, Sue 

Laferrere, Blandine B. 

Lakdawala, Muffazal Abdulkader 

Le Roux, Carel W. 

Lefevre, Frank 

Leibel, Rudolph L. 

Ley, Ruth 

Li, Rui 

McGraw, Timothy E. 

Mechanick, Jeffrey I. 

Mingrone, Geltrude 

Moore, John J. 

Pomp, Alfons 

Roth, Jesse 

Saoud, Mohammed Fathy 

Schwartz, Gary 

Shulman, Gerald 

Staten, Myrlene 

Sugerman, Harvey J. 

Sullivan, Sean D. 

Van Der Merwe, Tess 

Wolfe, Bruce 

Young, James 

Zimmet, Paul 

Zirie, Mahmoud Ali 


49



Visionary Level Supporter 

Corporate Sponsors 

Platinum Level 

Gold Level 

Silver Level 

Bronze Level 

We would also like to thank 

G.R.I.N. FOUNDATION 

50



www.wcidt.org 

Giovanni Lorenzini Medical Foundation 

6535 Fannin, MS A-601 

Suite A754 

Houston, TX 77030 

Tel: +1 713 797 0401 • Fax: +1 713 796 8853

2nd World Congress on Interventional Therapies for Type 2 Diabetes

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?